27
Feb
2012
Elevation Pharmaceuticals, Inc.: Series B $30M
Posted in I - Series B, Q - 1Q12, R - WEST, X - Asthma, X - COPD, XX - CA
Elevation Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on nebulized solutions for chronic obstructive pulmonary disease and asthma, closed a $30M Series B financing. Participants include Novo Ventures, Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners.
14
Feb
2012
26
Jul
2011
17
Jul
2011
F-Star, GmbH: Series B $21.7M
Posted in I - Series B, Q - 2Q11, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform
F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include SR One, MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.
02
Mar
2011
HTG, Inc.: Series D $15.7M
Posted in I - Series D, Q - 1Q11, R - SOUTH WEST, X - Device (Diagnostic), X - miRNA, X - mRNA, XX - AZ
HTG (Tuscon, AZ) a commercial-stage molecular technology company focused on gene expression profiling, miRNA and mRNA measurement, translational medicine and diagnostic applications, closed a $15.7M Series D financing. Participants include Novo Ventures, Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures.
01
Oct
2010
02
Sep
2010
16
Jun
2010
FoldRx Pharmaceutials, Inc.: Series C $29M
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Neuro Degenerative, X - Protein Folding, XX - MA
FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.
01
Jun
2010
Logical Therapeutics, Inc.: Series C $16.9M
Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - GI, X - Inflammation, X - NSAID, XX - MA
Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.
27
May
2010
21
May
2010
NeuroTherapeutics Pharma, Inc.: Series B $43M
Posted in I - Series B, Q - 2Q10, R - MID WEST, X - CNS, X - Epilepsy, X - Pain, XX - IL
NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.
01
Mar
2010
F-star Biotech, GmbH: Series A $10.8M
Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform
F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.
25
Feb
2010
Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.
OnBioVC PARTNERS
-
